Active Ingredient History
Inotuzumab ozogamicin, sold under the brand name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It is administered by intravenous infusion. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Antigens, CD (Phase 2)
Biomarkers (Phase 2)
Bone Marrow Cells (Phase 1/Phase 2)
Burkitt Lymphoma (Phase 1/Phase 2)
Hematopoietic Stem Cell Transplantation (Phase 2)
Leukemia (Phase 4)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Lymphoid (Phase 2)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1/Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 1/Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Lymphoma, Follicular (Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 3)
Lymphoma, Non-Hodgkin (Phase 3)
Testicular Neoplasms (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
